TRADE NAME: Fexinidazole (Sanofi ) INDICATIONS: Treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis due to Trypanosoma brucei gambiense . SYNONYM: Fexinidazole Winthrop CLASS: Antimicrobial , Antiprotozoal
FDA APPROVAL DATE: 07/16/2021 CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH: Adefovir , Bupropion , Carbamazepine , Cefaclor , Clarithromycin , Diazepam , Dofetilide , Duloxetine , Efavirenz , Erythromycin , Fluconazole , Furosemide , Itraconazole , Lansoprazole , Lovastatin , Mephenytoin , Metformin , Midazolam , Nisoldipine , Phenytoin , Rifampin , Saquinavir , Simvastatin , St John's Wort , Tacrine , Theophylline , Tizanidine , Voriconazole PREGNANCY: Insufficient to evaluate for a drug-associated risk of major birth defects or miscarriage.
Notes
Avoid concomitant use of herbal medicines and supplements
during treatment with fexinidazole.
Please login to view the rest of this drug profile.
Page last updated 01/16/2024